Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tatiana Nanovskaya is active.

Publication


Featured researches published by Tatiana Nanovskaya.


American Journal of Obstetrics and Gynecology | 2010

Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin

Sarah Hemauer; Svetlana Patrikeeva; Tatiana Nanovskaya; Gary D.V. Hankins; Mahmoud S. Ahmed

OBJECTIVE Substrates of placental efflux transporters could compete for a single transporter, which could result in an increase in the transfer of each substrate to the fetal circulation. Our aim was to determine the role of placental transporters in the biodisposition of oral hypoglycemic drugs that could be used as monotherapy or in combination therapy for gestational diabetes. STUDY DESIGN Inside-out brush border membrane vesicles from term placentas were used to determine the efflux of glyburide, rosiglitazone, and metformin by P-glycoprotein, breast cancer resistance protein, and multidrug resistance protein. RESULTS Glyburide was transported by multidrug resistance protein (43 +/- 4%); breast cancer resistance protein (25 +/- 5%); and P-glycoprotein (9 +/- 5%). Rosiglitazone was transported predominantly by P-glycoprotein (71 +/- 26%). Metformin was transported by P-glycoprotein (58 +/- 20%) and breast cancer resistance protein (25 +/- 14%). CONCLUSION Multiple placental transporters contribute to efflux of glyburide, rosiglitazone, and metformin. Administration of drug combinations could lead to their competition for efflux transporters.


American Journal of Obstetrics and Gynecology | 2008

Transfer of methadone across the dually perfused preterm human placental lobule.

Tatiana Nanovskaya; Ilona Nekhayeva; Gary D.V. Hankins; Mahmoud S. Ahmed

OBJECTIVE The objective of the study was to determine the effect of gestational age and P-glycoprotein expression on transplacental transfer of methadone. STUDY DESIGN Dual perfusion of placental lobule was utilized. Methadone (200 ng/mL) and its [3H]-isotope were cotransfused from the maternal-to-fetal circuit with the marker compound antipyrine (20 microg/mL) and its [14C]-isotope. Concentration of the drugs in trophoblast tissue and both circuits was determined by liquid scintillation spectrometry. RESULTS Fetal transfer rate of methadone in preterm placentas was 19 +/- 5.8%, and in term placentas it was 31 +/- 9.7% (P < .01). Clearance index of methadone in preterm placentas (0.57 +/- 0.2) was lower than in term placentas (0.95 +/- 0.3, P < .01). P-glycoprotein expression was higher in preterm than term placentas. CONCLUSION The ex vivo transfer of methadone across preterm placentas is 30% lower than in term placentas.


Biochemical Pharmacology | 2010

Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms

Sarah Hemauer; Tatiana Nanovskaya; Sherif Z. Abdel-Rahman; Svetlana Patrikeeva; Gary D.V. Hankins; Mahmoud S. Ahmed

The ABC transporter P-glycoprotein is a product of the MDR1 gene and its function in human placenta is to extrude xenobiotics from the tissue thus decreasing fetal exposure. The goal of this investigation was to examine the effect of three polymorphisms in the MDR1 gene on the expression and activity of placental P-gp. In 199 term placentas examined, the C1236T variant was associated with 11% lower P-gp protein expression than wild-type, while the C3435T and G2677T/A variants each were associated with a 16% reduction (p<0.05). Homozygotes for the C1236T and C3435T variant allele (TT) were associated with 42% and 47% increase in placental P-gp transport activity, respectively (p=0.04 and p=0.02) of the prototypic substrate, [(3)H]-paclitaxel. These findings indicate that the C3435T and G2677T/A SNPs in MDR1 are significantly associated with decreased placental P-gp protein expression, while the C1236T and C3245T homozygous variants are significantly associated with an increase in its efflux activity.


Biochemical Pharmacology | 2009

Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide

Olga L. Zharikova; Valentina M. Fokina; Tatiana Nanovskaya; Ronald A. Hill; Donald R. Mattison; Gary D.V. Hankins; Mahmoud S. Ahmed

One of the factors affecting the pharmacokinetics (PK) of a drug during pregnancy is the activity of hepatic and placental metabolizing enzymes. Recently, we reported on the biotransformation of glyburide by human hepatic and placental microsomes to six metabolites that are structurally identical between the two tissues. Two of the metabolites, 4-trans-(M1) and 3-cis-hydroxycyclohexyl glyburide (M2b), were previously identified in plasma and urine of patients treated with glyburide and are pharmacologically active. The aim of this investigation was to identify the major human hepatic and placental CYP450 isozymes responsible for the formation of each metabolite of glyburide. This was achieved by the use of chemical inhibitors selective for individual CYP isozymes and antibodies raised against them. The identification was confirmed by the kinetic constants for the biotransformation of glyburide by cDNA-expressed enzymes. The data revealed that the major hepatic isozymes responsible for the formation of each metabolite are as follows: CYP3A4 (ethylene-hydroxylated glyburide (M5), 3-trans-(M3) and 2-trans-(M4) cyclohexyl glyburide); CYP2C9 (M1, M2a (4-cis-) and M2b); CYP2C8 (M1 and M2b); and CYP2C19 (M2a). Human placental microsomal CYP19/aromatase was the major isozyme responsible for the biotransformation of glyburide to predominantly M5. The formation of significant amounts of M5 by CYP19 in the placenta could render this metabolite more accessible to the fetal circulation. The multiplicity of enzymes biotransforming glyburide and the metabolites formed underscores the potential for its drug interactions in vivo.


Biochemical Pharmacology | 2009

Opiates inhibit paclitaxel uptake by P-glycoprotein in preparations of human placental inside-out vesicles

Sarah Hemauer; Svetlana Patrikeeva; Tatiana Nanovskaya; Gary D.V. Hankins; Mahmoud S. Ahmed

The use of either methadone or buprenorphine for treatment of the pregnant opiate-dependent patient improves maternal and neonatal outcome. However, patient outcomes are often complicated by neonatal abstinence syndrome (NAS). The incidence and severity of NAS should depend on opiate concentration in the fetal circulation. Efflux transporters expressed in human placental brush border membranes decrease fetal exposure to medications by their extrusion to the maternal circulation. Accordingly, the concentration of either methadone or buprenorphine in the fetal circulation is, in part, dependent on the activity of the efflux transporters. The objective of this study was to characterize the activity of P-gp and its interaction with opiates in the placental apical membrane. Therefore, brush border membrane vesicles were prepared from human placenta. The vesicles were oriented approximately 75% inside-out, exhibited saturable ATP-dependent uptake of P-gp substrate [(3)H]-paclitaxel with an apparent K(t) of 66+/-38 nM and V(max) of 20+/-3 pmol mg protein (-1)min(-1). Methadone, buprenorphine, and morphine inhibited paclitaxel transport with apparent K(i) of 18, 44, and 90 microM, respectively. Our data indicate that a method has been established to determine the activity of the efflux transporter P-gp, expressed in placental brush border membranes, and the kinetics for the transfer of its prototypic substrate paclitaxel. Furthermore, the method was used to determine the effects of methadone, buprenorphine, and morphine on paclitaxel transfer by placental P-gp and revealed that they have higher affinity to the transporter than its classical inhibitor verapamil (K(i), 300 microM).


American Journal of Obstetrics and Gynecology | 2008

Transplacental transfer and metabolism of 17-α-hydroxyprogesterone caproate

Sarah Hemauer; Ru Yan; Svetlana Patrikeeva; Donald R. Mattison; Gary D.V. Hankins; Mahmoud S. Ahmed; Tatiana Nanovskaya

OBJECTIVE Determine transplacental transfer and metabolism of 17-alpha-hydroxyprogesterone caproate and its distribution between the tissue and the maternal and fetal circuits of the dually perfused placental lobule. STUDY DESIGN 17-alpha-Hydroxyprogesterone caproate (21 ng/mL) and its dual-labeled isotope, 17-alpha-hydroxy-[(3)H] progesterone [(14)C] caproate were added to the maternal circuit. The concentrations of the drug and its metabolite in trophoblast tissue and both circuits were determined by high performance liquid chromatography and liquid scintillation spectrometry. RESULTS 17-alpha-Hydroxyprogesterone caproate was transferred from the maternal to fetal circuit. After a 4-hour perfusion period, a metabolite of 17-alpha-hydroxyprogesterone caproate that retained both progesterone and caproate moieties was identified in the tissue and the maternal and fetal circuits. Neither 17-alpha-hydroxyprogesterone caproate nor its metabolite, at the concentrations tested, had adverse effect on determined viability and functional parameters of placental tissue. CONCLUSION 17-alpha-Hydroxyprogesterone caproate was metabolized by term placental lobule during its perfusion and both parent compound and its metabolite(s) transferred to the fetal circuit.


Journal of Maternal-fetal & Neonatal Medicine | 2008

Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide

Tatiana Nanovskaya; Svetlana Patrikeeva; Sarah Hemauer; Valentina M. Fokina; Donald R. Mattison; Gary D.V. Hankins; Mahmoud S. Ahmed

Objective. The aims of this investigation were (i) to determine the rate and extent of rosiglitazone transfer across term human placenta, and (ii) to determine the effect of human serum albumin (HSA) on rosiglitazone and glyburide transfer and distribution. Methods. These aims were achieved by utilizing the technique of dual perfusion of placental lobule (DPPL). Each hypoglycemic drug was coperfused with the marker compound antipyrine (AP). In each experiment, the [3H]-isotope of the hypoglycemic drug and the [14C]-isotope of AP were added to enhance the detection limits of each drug. Human serum albumin (HSA) was added to both the maternal and fetal circuits in the experiments in which it was investigated. Results. Transplacental transfer of rosiglitazone and glyburide from the maternal to fetal circuits in media devoid of HSA was similar. However, the addition of HSA to the maternal and fetal circuits had different effects on the transfer and distribution of the two drugs, though their binding to HSA (99.8%) was almost identical. HSA increased the maternal (M) to fetal (F) transfer of rosiglitazone, as revealed by an increase in its F/M concentration ratio from 0.17 ± 0.01 (in the absence of albumin) to 0.33 ± 0.07 (p < 0.001). Moreover, the addition of albumin decreased the amount of rosiglitazone retained by placental tissue from 539 ± 148 to 60 ± 8 ng/g (p < 0.001). Conversely, the addition of HSA to the perfusion media resulted in a decrease in glyburide transfer, as revealed by the change of its F/M concentration ratio from 0.09 ± 0.02 (in the absence of albumin) to 0.03 ± 0.01 (p < 0.01). However, similar to rosiglitazone, glyburide retention by the tissue decreased from 103 ± 26 to 19 ± 6 ng/g (p < 0.001). Conclusions. These data indicate that the binding of the two drugs to albumin, though similar, is only one of the factors that could affect their placental transfer and distribution.


Journal of Maternal-fetal & Neonatal Medicine | 2009

Transplacental transfer and metabolism of bupropion

Angela Earhart; Svetlana Patrikeeva; Xiaoming Wang; Doaa R. Abdelrahman; Gary D.V. Hankins; Mahmoud S. Ahmed; Tatiana Nanovskaya

Objective. In order to evaluate the potential use of bupropion as smoking cessation therapy during pregnancy, the aim of this investigation was to determine transplacental transfer and metabolism of bupropion and its distribution among placental tissue and maternal and fetal circuits of the dually perfused placental lobule. Methods. Placentas obtained from healthy term pregnancies were perfused with bupropion at two concentrations 150 ng/ml and 450 ng/ml, along with the marker compound antipyrine 20 μg/ml. Radioactive isotopes of the two drugs were co-transfused to enhance their detection limits. Concentrations of bupropion and its metabolite were determined by liquid chromatography and liquid scintillation spectrometry. Results. The fetal/maternal concentration ratio of bupropion was 1.07 ± 0.22. Following 4 h of its perfusion, 48 ± 6% of bupropion was retained by placental tissue, 32 ± 5% remained in the maternal circuit, and 20 ± 6% was transferred to the fetal circuit. A metabolite of bupropion, threohydrobupropion, was identified. Conclusions. Bupropion was transferred from the maternal to fetal circuit and was biotransformed by placental tissue enzymes to its metabolite threohydrobupropion. Bupropion and its metabolite did not affect placental tissue viability or functional parameters. These data suggest that bupropion has the potential of being used for smoking cessation during pregnancy and should be further investigated for its safety and efficacy.


Biochemical Pharmacology | 2010

Bupropion metabolism by human placenta

Xiaoming Wang; Doaa R. Abdelrahman; Olga L. Zharikova; Svetlana Patrikeeva; Gary D.V. Hankins; Mahmoud S. Ahmed; Tatiana Nanovskaya

Smoking during pregnancy is the largest modifiable risk factor for pregnancy-related morbidity and mortality. The success of bupropion for smoking cessation warrants its investigation for the treatment of pregnant patients. Nevertheless, the use of bupropion for the treatment of pregnant smokers requires additional data on its bio-disposition during pregnancy. Therefore, the aim of this investigation was to determine the metabolism of bupropion in placentas obtained from nonsmoking and smoking women, identify metabolites formed and the enzymes catalyzing their formation, as well as the kinetics of the reaction. Data obtained revealed that human placentas metabolized bupropion to hydroxybupropion, erythro- and threohydrobupropion. The rates for formation of erythro- and threohydrobupropion exceeded that for hydroxybupropion by several folds, were dependent on the concentration of bupropion and exhibited saturation kinetics with an apparent K(m) value of 40microM. Human placental 11beta-hydroxysteroid dehydrogenases were identified as the major carbonyl-reducing enzymes responsible for the reduction of bupropion to threo- and erythrohydrobupropion in microsomal fractions. On the other hand, CYP2B6 was responsible for the formation of OH-bupropion. These data suggest that both placental microsomal carbonyl-reducing and oxidizing enzymes are involved in the metabolism of bupropion.


Journal of Pharmaceutical and Biomedical Analysis | 2012

Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography-tandem mass spectrometry

Xiaoming Wang; Daria I. Vernikovskaya; Doaa R. Abdelrahman; Gary D.V. Hankins; Mahmoud S. Ahmed; Tatiana Nanovskaya

A liquid chromatography in tandem with electro-spray ionization mass spectrometry method has been developed and validated for the quantitative determination of bupropion and its major metabolites (hydroxybupropion, threo- and erythrohydrobupropion) in human umbilical cord plasma and placental tissue. The samples were acidified with trichloroacetic acid, and protein precipitated by adding acetonitrile. Chromatographic separation of drug and metabolites was achieved by using a Waters Symmetry C(18) column, with an isocratic elution of 31% methanol and 69% formic acid (0.04%, v/v) aqueous solution at a flow rate of 1.0 mL/min. Detection was carried out by mass spectrometry using positive electro-spray ionization mode, and the compounds were monitored using multiple reactions monitoring method. Deuterium-labeled isotopes of the compounds were used as internal standards. Calibration curves were linear (r(2)>0.99) in the tested ranges. The lower limit of quantification of analytes in umbilical cord plasma samples is <0.72 ng/mL and 0.92 ng/g in placental tissue samples. The relative deviation of this method was <15% for intra- and inter-day assays, and the accuracy ranged between 88% and 105%. The extraction recovery of the four analytes ranged between 89% and 96% in umbilical cord plasma, and 64% and 80% in placental tissue. No significant matrix effect was observed in the presented method.

Collaboration


Dive into the Tatiana Nanovskaya's collaboration.

Top Co-Authors

Avatar

Mahmoud S. Ahmed

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Gary D.V. Hankins

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Svetlana Patrikeeva

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Valentina M. Fokina

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Xiaoming Wang

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Olga L. Zharikova

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Sarah Hemauer

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Erik Rytting

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Ilona Nekhayeva

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Daria I. Vernikovskaya

University of Texas Medical Branch

View shared research outputs
Researchain Logo
Decentralizing Knowledge